Bringing Prostate Cancer Germline Genetics into Clinical Practice

Area of Science:

• Oncology
• Genetics
• Medical Research

Background:

• The role of germline genetics in prostate cancer management was previously undefined.
• Understanding genetic alterations is key to advancing patient care.

Purpose of the Study:

• To review the current understanding of germline genetic alterations in prostate cancer.
• To discuss clinical implications for genetic counseling, testing, early detection, and treatment.

Main Methods:

• Literature search of PubMed for articles since 2001 using keywords: "germline mutations," "BRCA," "family history," "prostate cancer genetics."
• Inclusion of data from governmental and professional organization websites.

Main Results:

• Germline mutations in DNA damage repair (e.g., BRCA1, BRCA2) and mismatch repair genes (e.g., MLH1, MSH2) are implicated in prostate cancer development.
• Genetic counseling and multipanel testing identify at-risk individuals, enabling cascade testing.
• Elevated cancer detection rates in BRCA carriers and positive responses to PARP inhibitors in metastatic castration-resistant prostate cancer patients with DNA damage repair defects were observed.

Conclusions:

• Germline genetic counseling and testing are becoming integral to prostate cancer management.
• Further research is required to define optimal screening, detection, and treatment strategies for individuals with germline mutations.